Skip to content

Compare U.S. Stocks

Put up to three companies side by side on valuation, growth, profitability, and debt.

Compare within a sector
MetricABVXAbivax SAGMABGenmab A/SINCYIncyte
Snapshot
Price$93.34$34.53$115.06
Market cap$11.63B$16.18B$23.35B
Valuation
P/E—20.9x16.1x
Forward P/E—27.9x11.5x
Growth
Revenue growth—20.7%21.5%
EPS growth—-25.3%2455.3%
Profitability
Net margin—21.1%26.7%
ROE-51.7%14.5%29.2%
Balance sheet & cash
Debt / equity0x0.93x0.01x
Free cash flow yield-2.1%—2.2%
Dividend yield———
Verdict
Investment ratingWeak· 35Favorable· 62Strong· 86

5-Year Price Projections

Base case

Projected using each stock's current EPS, growth rate (EPS or revenue growth), and P/E ratio. P/E assumed to compress 25% on the low end and remain steady on the high end. Not a forecast — for comparative analysis only.

YearABVXtoday $93GMABtoday $35INCYtoday $115
2027$74.91 – $109.86+18% CAGR$26.42 – $38.74+12% CAGR$2,205.10 – $3,234.15+2711% CAGR
2028$80.15 – $117.55+12% CAGR$26.94 – $39.52+7% CAGR$56,347.26 – $82,642.65+2580% CAGR
2029$85.76 – $125.78+10% CAGR$27.48 – $40.31+5% CAGR$1,439,847.23 – $2,111,775.94+2538% CAGR
2030$91.76 – $134.58+10% CAGR$28.03 – $41.11+4% CAGR$36,792,560.38 – $53,962,421.89+2517% CAGR
2031$98.19 – $144.01+9% CAGR$28.59 – $41.94+4% CAGR$940,163,974.57 – $1,378,907,162.71+2504% CAGR
5-yr CAGR1.0% – 9.1%-3.7% – 4.0%2312.4% – 2504.5%